Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib to Restore Radioiodine Uptake in RET Fusion-Positive Thyroid Cancer
NCT05668962Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of selpercatinib in thyroid cancer, sponsored by Massachusetts General Hospital. Started Mar 2023; status: recruiting.
02
Drugs
selpercatinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT05668962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668962.